Extended Data Fig. 6. Recruitment of tumor-promoting myeloid cells is prevented in PD-L2-KO tumors upon doxorubicin treatment.
(a) Percentage of NK cells (NK1.1+), macrophages (CD11b+ Gr1-) and lymphocytes (CD3+ TCRb+) relative to total CD45+ cells, in WT and PD-L2-KO tumors untreated or treated with doxorubicin at days 7 and 10, analysed by mass cytometry. N = 4 mice for all conditions. (b) Percentage of PD-1+ cells among subsets of infiltrating T cells, analysed by mass cytometry. N = 3 mice for WT + PBS and PD-L2-KO + doxo, n = 4 for WT + doxo and PD-L2-KO + PBS (c) Quantification of tumor infiltrating CD3+ lymphocytes in WT and PD-L2-KO tumors, untreated or treated with doxorubicin, analysed by immunohistochemistry. N = 4 for PBS-treated groups and n = 5 for doxo-treated groups. None of the changes were significant (1 way ANOVA, Tukey post-test). Data are presented as mean ± SEM. (d) Representative Gr1 stainings in sections of PD-L2-KO tumors treated with doxorubicin and subject to depletion of CD4+ (n = 8) or CD8+ (n = 9) T cells, as well as IgG-treated controls (n = 6) from Fig. 3c.